Citigroup cuts Moderna to Sell. Moderna stock faces a USD 80 target

Published on 10/20/2026 at 11:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Citi raised its target from USD 60 to USD 80 on October 14, 2026. Moderna stock costs EUR 201.65 on October 20, 2026, with USD 90.6 billion value.

Analyst view and company milestones

Citigroup moved Moderna to Sell and set a USD 80.00 target on October 14, 2026.
Second-quarter revenue reached USD 145.0 million on June 30, 2026.
Moderna stock traded at EUR 201.65 at Lang & Schwarz on October 20, 2026 at 11:29 a.m. CEST.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna Inc. (US60770K1079) faced a fresh valuation challenge after Citigroup downgraded the company to Sell and raised its price target from USD 60.00 to USD 80.00 on October 14, 2026. The call arrived as the stock traded near a USD 90.6 billion market value.

According to The Weekly Investor, Citigroup moved Moderna from Hold to Sell while increasing its target to USD 80.00. The change highlights the gap between a higher fundamental valuation and the share price, rather than a deterioration in the bank's stated target.

Three milestones shape the story

Moderna reported second-quarter 2026 revenue of USD 145.0 million and a GAAP net loss of USD 782.0 million for the period ended June 30, 2026. The loss improved by USD 43.0 million, or 5.00 percent, from the second quarter of 2025, while diluted GAAP earnings per share improved to a loss of USD 1.97 from USD 2.13, according to Yahoo Finance.

On August 28, 2026, Moderna announced pricing for USD 2.6 billion of convertible senior notes, with proceeds intended for general corporate purposes, oncology investment and debt repayment, according to Moderna. The financing adds balance-sheet capacity, but the quarterly loss shows that operating efficiency remains central to the investment case.

What does the target mean for valuation?

Citigroup's USD 80.00 target is below the company's USD 90.6 billion market value context and leaves the market focused on Moderna's oncology pipeline, vaccine sales and cash use. Moderna's 2026 plan calls for revenue growth of up to 10.00 percent, while management also expects third-quarter results to represent about 55.00 percent of second-half revenue, according to Yahoo Finance.

Two dates matter next

Moderna scheduled an investor event for October 24, 2026, and third-quarter 2026 financial results for November 6, 2026, according to Moderna. Nasdaq also announced that Moderna would join the Nasdaq-100 before the market opened on October 9, 2026, according to FinanzNachrichten.

Stock price and company profile

Moderna stock was trading at EUR 201.65 at Lang & Schwarz on October 20, 2026 at 11:29 a.m. CEST. The company is listed on Nasdaq under ticker MRNA and is a biotechnology business included in the Nasdaq-100. The further course of trading is shown by the continuously updated real-time quote of Moderna stock.